Zacks Research Forecasts Increased Earnings for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC) – Analysts at Zacks Research upped their FY2025 earnings estimates for shares of Henry Schein in a research note issued to investors on Monday, September 15th. Zacks Research analyst Team now forecasts that the company will earn $4.81 per share for the year, up from their prior estimate of $4.80. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2026 earnings at $1.38 EPS and Q2 2027 earnings at $1.39 EPS.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.09). Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.The business had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter in the prior year, the company earned $1.23 earnings per share. The company’s quarterly revenue was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS.

Other equities analysts also recently issued reports about the stock. Stifel Nicolaus restated a “hold” rating and set a $75.00 price objective (down from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. JPMorgan Chase & Co. cut their target price on shares of Henry Schein from $80.00 to $76.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Robert W. Baird reiterated a “neutral” rating and issued a $72.00 target price (down from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. UBS Group cut their target price on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. Five equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Henry Schein has an average rating of “Hold” and a consensus price target of $76.67.

Henry Schein Trading Down 1.5%

Henry Schein stock opened at $67.37 on Wednesday. The firm has a 50-day moving average of $68.98 and a 200-day moving average of $69.40. Henry Schein has a one year low of $60.56 and a one year high of $82.49. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The company has a market cap of $8.17 billion, a price-to-earnings ratio of 21.73, a P/E/G ratio of 2.26 and a beta of 0.86.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HSIC. CYBER HORNET ETFs LLC bought a new position in Henry Schein in the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein in the 2nd quarter valued at about $27,000. Investment Management Corp VA ADV bought a new position in shares of Henry Schein during the fourth quarter worth approximately $32,000. Rakuten Securities Inc. bought a new position in shares of Henry Schein during the first quarter worth approximately $34,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Henry Schein during the second quarter worth approximately $43,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.